Genomic Health to present its Oncotype DX multi-gene expression test studies at the 32nd SABCS

Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from five studies at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), taking place December 9-13, 2009, at the Henry B. Gonzalez Convention Center. Four of the studies analyze Oncotype DX®, the company's multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early-stage breast cancer.

Following are details for each embargoed session (all times are in Central Standard Time):

• Thursday, December 10, 2009, 5:30 p.m. - 7:30 p.m.

Abstract #112

Poster discussion (Poster Discussion 1 and Reception): "Prediction of 10-year chemotherapy benefit and breast cancer-specific survival by the 21-gene Recurrence Score (RS) assay in node-positive, ER-positive breast cancer - An update of SWOG-8814 (INT0100)"

Presenter: Kathy S. Albain, M.D., Professor, Division of Hematology/Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Director, Breast Clinical Research Program, Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Ill.

Location: Ballroom A

• Friday, December 11, 2009, 7 a.m. - 9 a.m.

Abstract: #2031

Poster presentation (Poster Session II): "Effect of 21-Gene Recurrence Score Results on Treatment Recommendations in Patients with Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer"

Presenter: Ruth Oratz, M.D., NYU School of Medicine, New York, NY

Location: Exhibit Halls A-B

• Saturday, December 12, 2009, 5:30 p.m. - 7:30 p.m.

Abstract: #5165

Poster presentation (Poster Session V): "Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways"

Presenter: Joseph Sparano, M.D., principal investigator for the Eastern Cooperative Oncology Group (ECOG) and director of the Breast Evaluation Center at the Montefiore-Einstein Cancer Center in New York, NY

Location: Exhibit Halls A-B

• Sunday, December 13, 2009, 7 a.m. - 8:30 a.m.

Abstract: #6004

Poster presentation (Poster Session VI): "HER2 amplification, Polysomy Status and Breast Cancer Survival in a Large Kaiser Permanente Case-Control Study: Assessment of HER2 by Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and Fluorescence in Situ Hybridization (FISH)"

Presenter: Rick Baehner, M.D., director of pathology at Genomic Health, Inc., and director of the Immunohistochemistry Core Laboratory at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco

Location: Exhibit Halls A-B

• Sunday, December 13, 2009, 7 a.m. - 8:30 a.m.

Abstract: #6021

Poster presentation (Poster Session VI): "Molecular Characterization of Breast Cancer Core Biopsy Specimens by Gene Expression Analysis Using Standardized Quantitative RT-PCR"

Presenter: Joseph Anderson, M.D., pathologist at Genomic Health, Inc.

Location: Exhibit Halls A-B